These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 15942045

  • 41. Enalapril prevents fatty liver in nephrotic rats.
    Toblli JE, Ferder L, Stella I, Angerosa M, Inserra F.
    J Nephrol; 2002; 15(4):358-67. PubMed ID: 12243364
    [Abstract] [Full Text] [Related]

  • 42. Attenuation of glomerular filtration barrier damage in adriamycin-induced nephropathic rats with bufalin: an antiproteinuric agent.
    Zheng J, Gong J, Zhang A, Li S, Zeng Z, Han Y, Gan W.
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):107-14. PubMed ID: 22207085
    [Abstract] [Full Text] [Related]

  • 43. Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats.
    Blezer EL, Nicolay K, Koomans HA, Joles JA.
    Am J Hypertens; 2001 Jan; 14(1):54-61. PubMed ID: 11206680
    [Abstract] [Full Text] [Related]

  • 44. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G.
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [Abstract] [Full Text] [Related]

  • 45. Combined renin angiotensin blockade in childhood steroid-resistant nephrotic syndrome.
    Supavekin S, Surapaitoolkorn W, Tancharoen W, Pattaragarn A, Sumboonnanonda A.
    Pediatr Int; 2012 Dec; 54(6):793-7. PubMed ID: 22621380
    [Abstract] [Full Text] [Related]

  • 46. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.
    Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M, Conti S, Rottoli D, Longaretti L, Remuzzi A, Remuzzi G, Benigni A.
    Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1448-56. PubMed ID: 19675181
    [Abstract] [Full Text] [Related]

  • 47. ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo.
    Vaughan MR, Pippin JW, Griffin SV, Krofft R, Fleet M, Haseley L, Shankland SJ.
    Kidney Int; 2005 Jul; 68(1):133-44. PubMed ID: 15954902
    [Abstract] [Full Text] [Related]

  • 48. [The additive antiproteinuric effect of Enalapril and Losartan to normotensive patients with pathology proteinuria].
    Liern M, Dieguez SM, De Reyes V, Vallejos G, Canepa C.
    Nefrologia; 2004 Jul; 24(6):553-8. PubMed ID: 15683027
    [Abstract] [Full Text] [Related]

  • 49. In vivo expression of podocyte slit diaphragm-associated proteins in nephrotic patients with NPHS2 mutation.
    Zhang SY, Marlier A, Gribouval O, Gilbert T, Heidet L, Antignac C, Gubler MC.
    Kidney Int; 2004 Sep; 66(3):945-54. PubMed ID: 15327385
    [Abstract] [Full Text] [Related]

  • 50. Temporal and spatial expression of podocyte-associated molecules are accompanied by proteinuria in IgA nephropathy rat model.
    Lu H, Chen LL, Jiang XY, Mo Y, Ling YH, Sun LZ.
    Physiol Res; 2013 Sep; 62(1):35-45. PubMed ID: 23173680
    [Abstract] [Full Text] [Related]

  • 51. Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR.
    Zhou X, Matavelli LC, Ono H, Frohlich ED.
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F871-9. PubMed ID: 15900021
    [Abstract] [Full Text] [Related]

  • 52. Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS.
    Doublier S, Zennaro C, Musante L, Spatola T, Candiano G, Bruschi M, Besso L, Cedrino M, Carraro M, Ghiggeri GM, Camussi G, Lupia E.
    PLoS One; 2017 Oct; 12(11):e0188045. PubMed ID: 29155846
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Podocyte differentiation and hereditary proteinuria/nephrotic syndromes.
    Gubler MC.
    J Am Soc Nephrol; 2003 Jun; 14 Suppl 1():S22-6. PubMed ID: 12761234
    [Abstract] [Full Text] [Related]

  • 57. Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome.
    Kosmadakis G, Filiopoulos V, Georgoulias C, Tentolouris N, Michail S.
    Scand J Urol Nephrol; 2010 Sep; 44(4):251-6. PubMed ID: 20201749
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Angiotensin II inhibition attenuates postexercise proteinuria in rats.
    Gündüz F, Kuru O, Sentürk UK.
    Int J Sports Med; 2005 Nov; 26(9):710-3. PubMed ID: 16237614
    [Abstract] [Full Text] [Related]

  • 60. Artemisinin ameliorated proteinuria in rats with adriamycin-induced nephropathy through regulating nephrin and podocin expressions.
    Wu X, An P, Ye B, Shi X, Dang H, Fu R, Qiao C.
    J Tradit Chin Med; 2014 Feb; 34(1):63-8. PubMed ID: 25102693
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.